Diabetes Diagnosis & Management Online 2017

Target Audience

This program should be of substantial interest to: endocrinologists and endocrine fellows, pediatric endocrinologists and pediatric endocrine fellows, endocrine physician’s assistants and internal medicine physicians who treat diabetes, geriatricians, nurses, and other healthcare professionals who treat patients with diabetes.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

Where Diabetes Technology Is and Where It’s Going

  • Discuss the current landscape of available technologies in the management of diabetes
  • Recognize the need for patient education to ensure successful use of technology in the personal management of diabetes

Novel Therapies for Type 2 Diabetes

  • Discuss the current landscape of available therapies in the management of T2D and the clinical impact of each
  • Review the effectiveness and utility of novel GLP1 agonist, and choose patients who are most appropriate for this class of medicines
  • Identify appropriate candidates for insulin pump therapy and/or continuous glucose monitor system with T2D


  • Screen patients for early clinical signs of NAFLD
  • Recognize the behavioral approaches to NAFLD management that are most impactful in practice
  • Select appropriate medical therapy options for the management of NAFLD in patients with T2D

Changing the Paradigm of Diabetes Prevention to Treating Pre-diabetes

  • Develop an approach to choosing a treatment strategy that is most optimal for managing pre-diabetes
  • Recognize the behavioral approaches to pre-diabetes management that are most impactful in practice
  • Explain the methods available for promoting lasting behavior change

Pediatric Diabetes                                                                  

  • Discuss the evolving prevalence of T1D and T2D in pediatric patients
  • Determine the most effect treatment strategies for managing diabetes in children
  • Recognize pediatric-specific barriers to compliance and recommend strategies to overcome them
  • Utilize insulin-dosing guidelines to adjust insulin regimen

The Statin Intolerant Patient

  • Identify blood pressure treatment targets and preferred pharmacologic treatment options for patients with diabetes
  • Describe the effectiveness of various classes of lipid-modifying therapies for CVD treatment and prevention in T2D

Treatment of Diabetes in the Older Adult

  • Recognize geriatric syndromes that increase risk for hypoglycemia
  • Modify glycemic goals in elderly patients at high risk for hypoglycemia
  • Recognize the appropriate medical management strategy to improve glycemic control in the elderly

CGM in 2017

  • Identify appropriate candidates for continuous glucose monitor system with type 1 or type 2 diabetes

Treatment of Hyperglycemia: Combination vs. Sequential Therapy

  • Determine the most effect strategies to advance therapy when managing hyperglycemia
  • Recognize patient barriers to compliance and suggest strategies to overcome them
  • Utilize insulin-dosing guidelines to adjust insulin regimen
  • Select therapies to manage hyperglycemia that takes patient factors into consideration

Modern Management of Type 1 Diabetes

  • Discuss the advances in stem cell and immunology research in T1D
  • Describe options for incorporating new therapies beyond insulin
  • Identify appropriate candidates for insulin pump therapy and/or continuous glucose monitor system
  • Recognize the need for patient education to ensure successful use of technology in the personal management of T1D

Can an Endocrinologist Improve Cardiovascular Outcomes through Glucose-Lowering Medications?

  • Summarize the most recent guideline recommendations for screening coronary artery disease in T2D including specific goals in reducing risk factors and appropriate biochemical targets
  • Explain cardiovascular complications, risk factors, screening guidelines, and recommended therapies for cardiovascular risk reduction for patients with T2D
  • Integrate new studies on cardiovascular outcomes trials into practice by incorporating cardiovascular considerations when selecting therapy for patients with T2D
  • Recognize practical implications of recent findings in EMPA-REG and LEADER trials on current treatment algorithms and future clinical studies

Therapeutic Strategies in Gestational Diabetes to Halt Type 2 Risk in Mom and Obesity in Offspring

  • Screen patients for early clinical signs of gestational diabetes using recent guidelines
  • Select appropriate medical therapy options for the management of gestational diabetes
  • Devise a follow-up plan for postpartum monitoring of patients with gestational diabetes

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Practice-based Learning and Improvement
Interpersonal and Communication Skills
Systems-based Practice
Topic Area: 
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Health Disparities
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 7.50 ABIM MOC
  • 7.50 AMA PRA Category 1 Credits
  • 7.50 CME Certificate of Participation
Course opens: 
Course expires: 

Program Chairs

John L. Leahy, MD; Univ of Vermont Coll of Med
Carol H. Wysham, MD; Rockwood Clin/Univ of Washington Sch of Med


Silva A. Arslanian, MD; Children's Hosp of Pittsburgh of UPMC
Linda A. Barbour, MD; Univ of Colorado Sch of Med
Richard M. Bergenstal, MD; HealthPartners Inst
Lawrence Blonde, MD; Ochsner Med Ctr
Kenneth Cusi, MD; Univ of Florida
Robert H. Eckel, MD; Univ of Colorado Sch of Med
Irl B. Hirsch, MD; Univ of Washington Med Ctr
Silvio E. Inzucchi, MD; Yale Sch of Med
Leigh Perreault, MD; Univ of Colorado Sch of Med
Richard E. Pratley, MD; Florida Hosp. Translational Res Inst for Metabolism and Diabetes
Willy M. Valencia, MD, MSc; Univ of Miami


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Richard M. Bergenstal, MD: Board Member, Abbott Laboratories

Lawrence Blonde, MD: Consultant, GlaxoSmithKline, Intarcia Therapeutics, Inc.; Consultant, Investigator, and Speaker, AstraZeneca, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc., Sanofi‐Aventis US, LLC; Investigator, Lexicon Pharmaceuticals, Inc.

Kenneth Cusi, MD: Consultant and/or Research Support, Janssen Pharmaceuticals, Inc., Novartis Pharmaceuticals, Novo Nordisk Inc., Octeta Therapeutics, LLC, Zydus Pharmaceuticals, Inc.

Robert H. Eckel, MD: Consultant, Merck & Co., Inc., Novo Nordisk Inc., Sanofi‐Aventis US, LLC; Researcher, Ionis Pharmaceuticals, Inc.; Independent Contractor (incl. contracted research), uniQure Inc.

Irl B. Hirsch, MD: Consultant, Abbott Laboratories, Intarcia Therapeutics, Inc., Roche Diagnostics, Valeritas, Inc.

Silvio E. Inzucchi, MD: Ad Hoc Consultant, Merck & Co., Inc., Janssen Pharmaceuticals, Inc.; Clinical Trial Executive Committee Member, AstraZeneca; Clinical Trial Steering Committee Member, Sanofi‐Aventis US, LLC; Data Monitoring Committee Member, Novo Nordisk Inc.; Publishing Committee Member, Boehringer Ingelheim Pharmaceuticals, Inc.

John L. Leahy, MD: Advisory Group Member, Johnson & Johnson, Merck & Co., Inc., Novo Nordisk Inc., Sanofi‐Aventis US, LLC

Leigh Perreault, MD: Advisory Board Member, Consultant, and/or Speaker, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Lilly USA, LLC, Merck & Co., Inc., Novo Nordisk Inc., Orexigen Therapeutics, Inc., Pfizer Inc., Sanofi‐Aventis US, LLC

Richard E. Pratley, MD: Consultant, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline, Hanmi Pharmaceutical Co., Ltd., Janssen Pharmaceuticals, Inc., Ligand Pharmaceuticals, Inc.; Consultant and Speaker, AstraZeneca; Consultant and Research Grant, Lexicon Pharmaceuticals, Inc., Lilly USA, LLC, Merck & Co., Inc., Takeda Pharmaceuticals U.S.A., Inc.; Consultant, Honoraria, Research Grant, and Speaker, Novo Nordisk Inc.; Research Grant, Sanofi‐Aventis US, LLC

Carol H. Wysham, MD: Advisory Group Member, Investigator, and Speaker, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly & Co., Janssen Pharmaceuticals, Inc., Sanofi‐Aventis US, LLC; Investigator and Speaker, Novo Nordisk Inc.

The following faculty reported no relevant financial relationships: Silva A. Arslanian, MD; Linda A. Barbour, MD; Willy M. Valencia, MD, MSc

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.


The Endocrine Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The Endocrine Society has achieved Accreditation with Commendation.The Endocrine Society designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC):

By completing this activity, you are eligible to earn a maximum of 7.5 American Board of Internal Medicine (ABIM) Medical Knowledge MOC points.

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile

Review & Edit your Profile


Available Credit

  • 7.50 ABIM MOC
  • 7.50 AMA PRA Category 1 Credits
  • 7.50 CME Certificate of Participation